Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | thromboxane A synthase 1 (platelet) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | cytochrome P450, putative | thromboxane A synthase 1 (platelet) | 534 aa | 498 aa | 21.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0576 | 0.0151 | 0.0151 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.1143 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.1143 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.1143 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.1143 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.1143 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1143 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.1143 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1143 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.1143 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.1143 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0706 | 0.2407 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1143 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1143 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.1143 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.1143 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0567 | 0 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.1143 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.1013 | 0.7743 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.1143 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0567 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.1143 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.1143 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.1143 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0706 | 0.2407 | 0.2407 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.1013 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1143 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.1143 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.1143 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 1 mg kg-1 | Thromboxane synthase inhibitor (TxSI) activity assessed by ex vivo inhibition of serum TXB2 production in rat after Intravenous administration | ChEMBL. | 11858999 |
ED50 (functional) | = 1 mg kg-1 | Thromboxane synthase inhibitor (TxSI) activity assessed by ex vivo inhibition of serum TXB2 production in rat after Intravenous administration | ChEMBL. | 11858999 |
ED50 (functional) | = 1.35 mg kg-1 | Antagonism of Platelet activating factor (PAF)in mice after Intravenous administration, assayed by PAF-induced death | ChEMBL. | 11858999 |
ED50 (functional) | = 1.35 mg kg-1 | Antagonism of Platelet activating factor (PAF)in mice after Intravenous administration, assayed by PAF-induced death | ChEMBL. | 11858999 |
ED50 (functional) | > 10 mg kg-1 | Antagonism of Platelet activating factor (PAF) activity in mice after oral administration, assayed by PAF-induced death | ChEMBL. | 11858999 |
ED50 (functional) | > 10 mg kg-1 | Thromboxane synthase inhibitor (TxSI) activity was assessed by ex vivo inhibition of serum TXB2 production in rat after oral administration | ChEMBL. | 11858999 |
ED50 (functional) | > 10 mg kg-1 | Antagonism of Platelet activating factor (PAF) activity in mice after oral administration, assayed by PAF-induced death | ChEMBL. | 11858999 |
ED50 (functional) | > 10 mg kg-1 | Thromboxane synthase inhibitor (TxSI) activity was assessed by ex vivo inhibition of serum TXB2 production in rat after oral administration | ChEMBL. | 11858999 |
IC50 (functional) | = 0.046 uM | Inhibition of Platelet activating factor (PAF)- induced platelet aggregation in rabbit platelet rich plasma (PRP) | ChEMBL. | 11858999 |
IC50 (functional) | = 0.08 uM | In vitro inhibition of thromboxane synthase (TXA2) in human platelet microsomes [reduced formation of TXB2 from prostaglandin H2(PGH2)] | ChEMBL. | 11858999 |
IC50 (functional) | = 0.08 uM | In vitro inhibition of thromboxane synthase (TXA2) in human platelet microsomes [reduced formation of TXB2 from prostaglandin H2(PGH2)] | ChEMBL. | 11858999 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.